8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): November 29, 2005

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))














Item 5.02  Departure of Directors or Principal Officers; Election of
           Directors; Appointment of Principal Officers

Effective November 29, 2005, Dr. Charles A. Dinarello was elected to the Board
of Directors of Techne Corporation (the "Company") and to the Nominations and
Governance Committee of the Board. In connection with his service on the
Company's Board and the Nominations and Governance Committee, Dr. Dinarello will
receive annual cash compensation and stock options pursuant to the Company's
director compensation policy.

Dr. Dinarello was not named as director pursuant to any arrangement or
understanding with any third person.  There is not currently, nor has there been
in the past, any transaction with the Company or any of its subsidiaries or
affiliates in which Dr. Dinarello has or had a direct or an indirect material
interest.

On November 29, 2005, the Company issued a press release announcing the election
of Dr. Dinarello to the Company's Board of Directors.  The press release is
attached as Exhibit 99.1 and is incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

        99.1   Press Release dated November 29, 2005.







                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: November 30, 2005               TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated November 29, 2005.

EX-99.1

     TECHNE CORPORATION ANNOUNCES THAT DR. CHARLES A. DINARELLO HAS
                    ACCEPTED A SEAT ON TECHNE'S BOARD.

Minneapolis/November 29, 2005/--TECHNE Corporation (NASDAQ: TECH) announced
today that Dr. Charles A. Dinarello has accepted a Director position on
TECHNE's Board of Directors.  Dr. Dinarello's initial term will begin
immediately and run through October 26, 2006.  All TECHNE Directors are
reelected by its shareholders on an annual basis.

Dr. Dinarello is a Professor of Medicine at the University of Colorado School
of Medicine in Denver.  Until 1996, he was Professor of Medicine and
Pediatrics at Tufts University School of Medicine and a staff physician at
the New England Medical Center Hospital in Boston.  Dr. Dinarello received
his medical degree from Yale University and his clinical training at the
Massachusetts General Hospital.  From 1971 to 1974, he was a clinical
associate and from 1975 to 1977 a senior investigator at the National
Institutes of Health in Bethesda.  Dr. Dinarello has published over 500
original research articles on cytokines, particularly Interleukin-1 and Tumor
Necrosis Factor.  The Institute for Scientific Information listed him as the
world's fourth most cited scientist (all science) for the 20 years (1983-
2003).  He was elected into the United States National Academy of Sciences in
1998 and is currently a member of the editorial board of "Proceedings of the
National Academy of Sciences."

He has trained over 40 investigators, many of whom are recognized experts in
their fields.  Dr. Dinarello has served on the Board of Scientific Advisors
of the National Institutes of Allergy and Infectious Diseases and is
currently on the Board of Advisors of the Alliance for Lupus Research.  He
was Vice President of the American Society of Clinical Investigation (1989-
1990) and President of the International Cytokine Society (1995-1996).  The
recipient of several awards for his contributions to the field of infectious
diseases and cytokines, he received Germany's Ernst Jung Prize in Medicine in
1993.  He donated the entire prize money ($125,000) to universities and
research institutes in the United States and Israel, and established the
Sheldon M. Wolff Professorship at Tufts University to honor his late mentor.
In 1996, he received the Ludwig Heilmeyer Gold Medal of the Society for
Internal Medicine (Germany, Austria, and Switzerland) for his contributions
to progress in internal medicine.  He is also the recipient of the Chirone
International Prize from the Italian Academy of Medicine.  In 1997, the
University of Marseille (France) conferred upon Dr. Dinarello the degree
Doctor Honoris Causa and most recently he received an honorary doctorate from
the Weizmann Institute of Science in Israel.

Mr. Thomas E. Oland, TECHNE's Chairman and CEO, said "I am extremely pleased
with Dr. Dinarello's decision to accept a position on TECHNE's Board.  We are
very fortunate to have a person of his scientific caliber on our Board.  Dr.
Dinarello is one of the world's leading researchers, having led the team that
was the first to clone the human gene for Interleukin-1 in 1984, which opened
the field known today as cytokine biology.   He is actively involved in
research on a day-to-day basis and is currently studying the biology of
Interleukin-IL-32, a new cytokine recently discovered in his laboratory.  His
unique scientific expertise in the area of cytokine biology, knowledge of our
research market as a bench scientist, as well as a clinician, will be of an
immense benefit to Techne as we formulate plans for research and new product
development, particularly in the area of diagnostics that could help humans
with debilitating and life-threatening diseases. I am very confident that he
will make a significant contribution to our future success."

Forward Looking Statements:
This press release may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Forward-looking statements involve
risks and uncertainties that may affect the actual results of operations.
The following important factors, among others, have affected and, in the
future, could affect the Company's actual results: the integration of the
recent acquisitions, the introduction and acceptance of new biotechnology and
hematology products, the levels and particular directions of research by the
Company's customers, the impact of the growing number of producers of
biotechnology research products and related price competition, the retention
of hematology OEM and proficiency survey business, the impact of currency
exchange rate fluctuations, and the costs and results of research and product
development efforts of the Company and of companies in which the Company has
invested or with which it has formed strategic relationships.  For additional
information concerning such factors, see the Company's annual report on Form
10-K and quarterly reports on Form 10-Q as filed with the Securities and
Exchange Commission.  We undertake no obligation to update or revise any
forward-looking statements we make in this release due to new information or
future events.  Investors are cautioned not to place undue emphasis on these
statements.

            **********************************************

Techne Corporation has two operating subsidiaries: Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
Fortron Bio Science, Inc. (Fortron), located in Minneapolis, and BiosPacific,
Inc. (BiosPacific), located in Emeryville, California.  Fortron develops and
manufactures antibodies and BiosPacific is a worldwide supplier of biologics
to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
R&D Europe is a distributor of biotechnology products.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
           (612) 379-8854